<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217382</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0636</org_study_id>
    <nct_id>NCT04217382</nct_id>
  </id_info>
  <brief_title>Pre Transplantation Melanoma</brief_title>
  <acronym>MPG</acronym>
  <official_title>Pre Transplantation Melanoma : Retrospective and Prospective Multicenter Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melanoma incidence is increase in global population and number of transplantation also.
      However immunosuppressor increase recurrence risk of melanoma.

      There are more and more cases of eligible patients to transplant with an antecedent of
      melanoma. There is no guideline yet.

      Main objective is survival time without melanoma recurrence in this population to do
      guideline of time limit or not between melanoma and transplantation by stage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">February 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>survival time without melanoma recurrence</measure>
    <time_frame>at enrollment</time_frame>
    <description>Delay in recurrence-free survival since diagnosis and since transplantation</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patient with melanoma pre transplantation</intervention_name>
    <description>survival time without melanoma recurrence</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with an antecedent of melanoma before transplantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with an antecedent of melanoma before transplantation

          -  Not opposite to participate

        Exclusion Criteria:

          -  Under the age of 18

          -  patient under Guardianship

          -  patient not affiliated with a health system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie DUCROUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Dermatologie, HÃ´pital Edouard Herriot, Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie DUCROUX, MD</last_name>
    <phone>0472110324</phone>
    <phone_ext>+33</phone_ext>
    <email>Emilie.ducroux@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion PATRAS, Resident</last_name>
    <phone>0472110324</phone>
    <phone_ext>+33</phone_ext>
    <email>marion.patras@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>service de dermatologie - hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>emilie DUCROUX, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

